Slate CEO says 5 types of car shoppers are interested in its low-cost EV pickup
The demographic groups included fresh college graduates, newly-licensed drivers, and retirees, she told Sherwood News.
The Jeff Bezos-backed company initially promised a truck "under $20,000," but shifted to a "mid-twenties" expected price tag.
Slate Auto's new electric vehicle is expected to be unusually cheap, priced in the mid-twenty-thousand-dollar range.
Given its anticipated price point, Slate says it has seen interest from five different consumer segments as it prepares to enter the market, CEO Chris Barman said in a recent interview with Sherwood News.
First, Barman said that "everyday Americans" are interested in the vehicle, mostly because "it's just an affordable vehicle and a lot of utility and value for the money."
Barman also said that "young professionals" fresh out of college or trade school are interested. "They're looking for value for the money, and what they love is the fact that it's an EV and they love the customization," she said.
Electric vehicle ownership has long veered younger, according to a March Gallup poll, with 64% of 18-34-year-olds surveyed interested in owning an EV, compared to just 41% of those ages 55+. Barman is eyeing an especially young demographic: newly licensed drivers.
"Parents like the fact that there are only two passengers, it doesn't have an infotainment for distraction, it has really high safety standards, and it's affordable," Barman told Sherwood.
Among the older set, Barman points out that "contemporary seniors" are interested in the vehicle. "
"They're individuals who are semiretired or retired and are interested in an electric vehicle, but have been intimidated by all the other technology that has been in an EV," she said. "They just want a simpler form of driving."
Finally, auto junkies are interested in tricking the car out, the CEO added.
Slate's electric pickup truck's "mid-twenties" price target remains relatively inexpensive, a feat especially important as the EV market floods with Chinese competitors outside of the US.
The Jeff Bezos-backed EV producer originally said that its truck would be "under $20,000" after federal incentives. That price would have made the truck substantially cheaper than its EV competitors, like the Nissan Leaf, which starts at $28,140.
When $50 reservations opened in April, the company reported receiving more than 100,000 requests in the first three weeks.
President Donald Trump's "One Big Beautiful Bill Act" is set to eliminate many of the country's clean energy incentives, including the $7,500 tax credit for new US-built EVs, which Slate had been counting on to hit the sub-$20,000 pricing threshold.
After Trump's spending bill was signed into law on July 4, Slate Auto changed the expected price online from "under $20,000" to "mid-twenties," where it remains.
Read the original article on Business Insider
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
13 minutes ago
- CNBC
If Apple makes a foldable phone, analysts say this stock will benefit
Even if Apple's long-awaited foldable may still be months or years away, buyers are lining up for a potential major supplier: Chinese glass maker Lens Technology . It's "one of the key beneficiaries of [the] foldable iOS smartphone supply chain," Citi analysts led by Kyna Wong said in a July 14 report about Lens Tech. They estimate the device could contribute to 5% of the Chinese company's revenue next year, and 12% in 2027. In a report last week, reputable Apple analyst Ming-Chi Kuo kept up expectations that the iPhone maker will begin making a foldable next year. Apple has not made any announcements, and did not immediately respond to a request for comment on whether Lens Tech would provide the "ultra thin glass" that covers the phone display panel. The Citi report initiated coverage of Lens Tech after its stand out Hong Kong public offering on July 9 — raising 4.77 billion HKD ($610 million) on the exchange's busiest day ever for listings — five IPOs at once. Bank of America Securities was one of the underwriters. The Citi analysts rate Lens Tech a buy, with a price target of 26 HKD ($3.13), or nearly 25% upside from Friday's close. "We believe the H-share listing is positive for the company," the analysts said, "as it should provide more cash for potential R & D initiatives and overseas capacity expansion, and expand the overseas institutional investor base." U.S. hedge fund magnate Steve Cohen has jumped in, with multiple purchases over three days that brought his stake in Lens Tech to 8.41% of issued voting shares, according to filings with the Hong Kong stock exchange. About 30% of proceeds raised from the Hong Kong offering will go towards developing foldable screens, Lens Tech said in its prospectus. "By increasing our production capacity in China, we aim to ensure robust support for the mass production of middle and high-end foldable smartphones for our customers and improve our market share in foldable screens," the company said. Lens Tech did not name Apple, but disclosed that its largest customer has been a Nasdaq-listed U.S. multinational founded in 1976 — and said the business relationship started "almost two decades ago when Customer/Supplier A was developing the industry's first touch-enabled smartphone with full-sized screen." Lens Tech's latest listing follows a trend this year of more mainland Chinese companies going public in Hong Kong, which is easier for international investors to access. The company already trades on the Shenzhen Exchange. "We expect Lens to benefit from the foldable iPhone launch [and] AI glasses & robotics" that drive earnings growth of at least 20% a year in 2026 and 2027, UBS analyst Zoe Xu and a team said in a separate July 14 report. They resumed coverage of the mainland China-traded shares with a buy rating and a new price target of 26.20 yuan, up from 16 yuan previously. The Citi analysts also raised their price target on Lens Tech's mainland-traded shares to 32 yuan ($4.45) from 25 yuan. Lens Tech has been reducing its reliance on Apple revenue, and states in its prospectus that "Customer B" is a "Nasdaq-listed American company founded in 2003 that designs and sells smart vehicles." Other listed customers include South Korean, French and Chinese companies. The UBS analysts pointed out that Lens Tech shares remain depressed after a 30% tumble in the week following U.S. "Liberation Day" tariffs in early April. But they expect the company can benefit from selling to Chinese startups such as smart glasses company Rokid and Zhiyuan Robotics. And even without a potential foldable iPhone, Lens Tech can likely benefit from selling cover glass for this year's iPhone 17 which is expected to offer a slimmer design. Lens Tech noted in its prospectus that its direct exports to the U.S. are limited and that it plans to use Hong Kong listing proceeds to expand production overseas in Vietnam and Thailand. In addition to China, the company said it already has factories in Vietnam and Mexico. — CNBC's Michael Bloom contributed to this report.
WIRED
13 minutes ago
- WIRED
How to Limit Galaxy AI to On-Device Processing—or Turn It Off Altogether
You don't have to accept the AI that Samsung offers you. Samsung Galaxy S25 Edge smartphones are displayed during a media preview in New York, US, on Friday, May 9, 2025. Photograph:All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Artificial intelligence is now more pervasive than ever in the apps and gadgets we use day to day, and that of course extends to smartphones: Google Gemini on Pixels and other Android handsets, Apple Intelligence (currently still rolling out) on iPhones, and Galaxy AI on Samsung smartphones. These tools can help you refine text, generate images, and summarize documents, among other tricks, and you don't have to go far through your apps to find an AI feature ready and willing to help you with something. With Samsung Galaxy AI, you have the option to disable the AI features you don't want to use, or switch off artificial intelligence altogether. If you're on one of the latest Galaxy S25 phones (with the fastest, AI-capable chips), you also get the option to keep most of the AI enabled but process it on your device, without transferring anything to the cloud. How Samsung Galaxy AI Works Galaxy AI is spread right through the latest One UI 6 and One UI 7 software updates from Samsung. More recent additions include the Now Brief screen that aims to bring you the information you need the most at the right time, and the Audio Eraser tool for quickly removing background noise from videos. There are generative AI editing tools for your photos, and generative AI writing options for your emails and messages. If you're not happy with the way a block of text reads or the way a picture is looking, you can deploy some Galaxy AI magic and make changes with a few well-chosen prompts. Galaxy AI is only ever a few taps away. Photograph: David Nield This all requires some pretty deep access to your apps and to your data, which is one reason to carefully consider whether or not you want to use these tools. For example, Galaxy AI has to be able to read your email in order to rewrite it, and some of the data you're asking the AI to work with may be traveling to and from Samsung's servers for processing. Samsung says that all Galaxy AI data is securely encrypted and protected from prying eyes, though of course no security protection can ever be guaranteed to be fully 100 percent effective all of the time. You can find the full Samsung privacy policy online. How to Turn Galaxy AI Features On or Off Perhaps you're not sure about allowing Galaxy AI access to everything you're writing and editing, or maybe you just find the AI features a little too pushy. On Galaxy smartphones, you've got the option to turn off some or all of these features. To see the AI features that are currently active, open up Settings, then choose Galaxy AI. You get a full list of what the AI can do on Samsung phones, and it might be more comprehensive than you realized: everything from transcribing voice recordings to giving you personalized insights into your fitness data. You can access all the Galaxy AI features from the same menu. Photograph: David Nield Tap on any of these Galaxy AI features to make changes. The exact options you see will depend on the feature, and some of these features come with sub-features, but they all come with toggle switches for turning the tools on or off. You also get descriptions for how your data is managed. Select Photo assist, for example, and there are three tools listed: Generative edit (using AI to remove and move objects in images), Sketch to image (for turning basic outlines into photos), and Portrait studio (for turning photos of people into cartoons and sketches). Use the toggle switch at the top to turn all these features on or off. How to Enable On-Device Processing Open Galaxy AI from Settings on a Samsung Galaxy S25 phone, and you'll see a Process data only on device toggle switch at the bottom of the AI feature list. These phones have Snapdragon 8 Elite chipsets inside them, with powerful enough AI processing capabilities to take care of some jobs without transferring data to and from the cloud. That's some jobs, not all jobs; you'll see that some of the features are no longer available when you flick the toggle switch for on-device processing. Samsung doesn't provide a definitive list of which features can work without the cloud, but automatic summaries and generative AI editing are among those mentioned as needing internet access. On-device processing is more private, but limits some features. Photograph: David Nield There are also a few Process data only on device toggle switches available inside the Galaxy AI feature menus—there's one for Writing assist, for example. You can still use the feature without accessing the cloud, but the number of languages available to you for translations is reduced, because you're relying on local files. Overall, there's a good amount of control here, letting you strike your preferred balance between Galaxy AI features, software bloat, and data privacy. No doubt there are more Galaxy AI features to come further down the line, so be sure to check this list regularly to see what you have access to on your device.
Yahoo
15 minutes ago
- Yahoo
3 Penny Stocks With Market Caps Over $70M Worth Watching
Over the last 7 days, the market has remained flat, while in the past 12 months it has risen by 14%, with earnings expected to grow by 15% per annum over the next few years. For investors willing to explore beyond established names, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities. Although "penny stocks" might seem like an outdated term, their potential for growth and affordability remains significant, especially when these companies boast strong financials and balance sheet resilience. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.70 $524.41M ★★★★★★ CuriosityStream (CURI) $4.46 $249.3M ★★★★★★ WM Technology (MAPS) $0.9714 $159.1M ★★★★★★ Perfect (PERF) $2.37 $234.25M ★★★★★★ Tuniu (TOUR) $0.9326 $100.29M ★★★★★★ Safe Bulkers (SB) $4.13 $414.36M ★★★★☆☆ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.83 $6.01M ★★★★★★ Lifetime Brands (LCUT) $4.68 $99.74M ★★★★★☆ North European Oil Royalty Trust (NRT) $4.96 $43.75M ★★★★★★ Click here to see the full list of 417 stocks from our US Penny Stocks screener. Let's review some notable picks from our screened stocks. Zura Bio Simply Wall St Financial Health Rating: ★★★★★★ Overview: Zura Bio Limited is a clinical-stage biotechnology company focused on developing medicines for immune and inflammatory disorders in the United States, with a market cap of $79.82 million. Operations: No revenue segments have been reported. Market Cap: $79.82M Zura Bio, a clinical-stage biotechnology company with a market cap of US$79.82 million, is currently pre-revenue, highlighting its early development stage. The recent appointment of Eric Hyllengren as CFO brings extensive financial leadership experience from the biotech sector, potentially strengthening Zura's strategic finance and operational execution. Despite having no debt and sufficient cash runway for over three years, the company's shares are highly volatile and it faces challenges such as being dropped from several growth benchmarks while being added to value indices. Its ongoing Phase 2 trial for tibulizumab reflects active efforts in drug development amidst these transitions. Click here to discover the nuances of Zura Bio with our detailed analytical financial health report. Examine Zura Bio's earnings growth report to understand how analysts expect it to perform. Nextdoor Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Nextdoor Holdings, Inc. operates a neighborhood network that connects neighbors, businesses, and public agencies both in the United States and internationally, with a market cap of approximately $696.31 million. Operations: The company generates revenue of $248.31 million from its Internet Information Providers segment. Market Cap: $696.31M Nextdoor Holdings, Inc., with a market cap of US$696.31 million, trades significantly below its estimated fair value and remains debt-free. Despite being unprofitable with a negative return on equity and no forecasted profitability in the next three years, the company maintains sufficient cash runway for over three years without significant shareholder dilution recently. Recent developments include a major redesign of its platform to enhance user engagement through features like Alerts, News, and Faves. Additionally, Nextdoor has expanded advertising into Canada and completed a substantial share buyback program aimed at enhancing shareholder value. Unlock comprehensive insights into our analysis of Nextdoor Holdings stock in this financial health report. Understand Nextdoor Holdings' earnings outlook by examining our growth report. Elite Pharmaceuticals Simply Wall St Financial Health Rating: ★★★★★★ Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals, with a market cap of approximately $567.50 million. Operations: The company's revenue is primarily derived from its Abbreviated New Drug Applications (ANDA) segment, which generated $84.04 million. Market Cap: $567.5M Elite Pharmaceuticals, Inc., with a market cap of US$567.50 million, has shown revenue growth to US$84.04 million for the year ended March 31, 2025, despite reporting a net loss of US$4.31 million compared to the previous year's net income. The company maintains financial stability with short-term assets exceeding both short and long-term liabilities and has reduced its debt-to-equity ratio significantly over five years. Although unprofitable, Elite's operating cash flow covers its debt well and it hasn't seen meaningful shareholder dilution recently. However, significant insider selling in recent months could be a concern for potential investors. Dive into the specifics of Elite Pharmaceuticals here with our thorough balance sheet health report. Review our historical performance report to gain insights into Elite Pharmaceuticals' track record. Where To Now? Explore the 417 names from our US Penny Stocks screener here. Searching for a Fresh Perspective? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ZURA KIND and ELTP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
